ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.

Also Announces Gary Maingot as SVP, Operations; New Executive Leadership Team Members Contribute Deep Functional Expertise and Technical Knowledge; Inducement Grants Reported Also Announces Gary Maingot as SVP, Operations; New Executive Leadership Team Members Contribute Deep Functional Expertise and Technical Knowledge; Inducement Grants Reported

Conformis Appoints Bob Howe as Chief Financial Officer

Conformis: An Update On The New Total Hip Replacement System

Conformis’ Patient-Specific Knee Implant Technology Is Complemented by New 3D-designed Hip System Launched in November 2019 Conformis’ Patient-Specific Knee Implant Technology Is Complemented by New 3D-designed Hip System Launched in November 2019

Conformis Achieves 100,000 Implant Milestone for Patient-Specific Knee Replacement Technology

BILLERICA, Mass. and SAN FRANCISCO, Jan.  14, 2020  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient’s unique anatomy, today announced preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2019.

Conformis Reports Preliminary Fourth Quarter and Year-End 2019 Revenue Results

Athenex

Boston Scientific

Dare Bioscience

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Achillion Pharmaceuticals

Digital Turbine

EverBank Financial

iShares Russell 2000 ETF

Kodiak Sciences Inc

Inside the best performing stocks of the Russell 2000 ETF.

5 Stocks That Pushed Russell 2000 ETF Higher

Conformis' (CFMS) CEO Mark Augusti on Q3 2019 Results - Earnings Call Transcript

BILLERICA, Mass., Oct.  04, 2019  (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants designed to fit each patient’s unique anatomy, announced today that Paul Weiner, Chief Financial Officer, has notified the Company that he will be departing the Company on October 18, 2019 to become the Chief Financial Officer at a privately-owned business in Fremont, CA.

Conformis Announces Departure of Paul Weiner, CFO

Conformis Inc. (NASDAQ: CFMS) shares shot up on Tuesday after the firm announced that it has entered into definitive agreements to sell and license to Stryker Corp.

Would Stryker Be Better Off Buying Conformis?

The soon to be released total hip system is being undervalued by the market.

Conformis: The Short-Term Challenges Are Overshadowing Significant Long-Term Opportunities

Conformis' (CFMS) CEO Mark Augusti on Q2 2019 Results - Earnings Call Transcript

Flexible Solutions

Orion Energy Systems

These low-priced stocks are attracting healthy buying interest despite sub-par small-cap performance so far in 2019.

3 Stocks Under $5 Hitting New Highs

Conformis' (CFMS) CEO Mark Augusti on Q1 2019 Results - Earnings Call Transcript

ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

News for ConforMIS Stock (CFMS)